Our goal is to establish the pHLIP® Platform Technology as a standard of care for targeted therapeutics.
Our business strategy is to develop pHLIP® applications ourselves and through partnership and collaboration.
Cybrexa Therapeutics holds exclusive rights for the development of therapeutic agents based on use of pH-sensitive peptides, pHLIP®, for targeted delivery of some DNA repair inhibitors and some cytotoxic molecules.
pHLIP, Inc. has exclusive rights to a comprehensive and growing IP portfolio built by the team of Dr. Ingrid A. Beattie, a member at Mintz Levin.
Integral to our business strategy is proliferation of our technology via multiple partnering and out-licensing in other fields and indications: Please contact us